User:Mr. Ibrahem/Paliperidone

Paliperidone, sold under the trade name Invega among others, is an atypical antipsychotic used to treat schizophrenia and schizoaffective disorder. It may be taken by mouth or injected into a muscle. When the unpublished literature is included, benefits are lower and harms are higher than when only the published literature is looked at.

Common side effects include headache, trouble sleepiness, parkinsonism, involuntary muscle movements, dizziness, agitation, depression, weight gain, nausea, dry mouth, QT prolongation, and tiredness. Other side effects may include neuroleptic malignant syndrome, tardive dyskinesia, diabetes, and high prolactin. In older people with dementia, use increases the risk of death. Use during pregnancy may have negative effects on the baby. Benefits are believed to be due to effects on dopamine and serotonin.

Paliperidone was approved for medical use in the United States in 2006 and Europe in 2007. It is on the World Health Organization's List of Essential Medicines. In the United Kingdom the typical dose by mouth cost the NHS about £105 per month as of 2021. This amount in the United States costs about 400 USD.